O. Sitbon (Clamart, France), J. Pepke-Zaba (Cambridge, United Kingdom)
Deleterious effects of ß-blockers on exercise capacity and hemodynamics in portopulmonary hypertension S. Provencher, P. Hervé, V. Ioos, X. Jais, D. Lebrec, M. Humbert, G. Simonneau, O. Sitbon (Clamart, Clichy, France)
| |
Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy H. J. Seyfarth, S. Hammerschmidt, H. Pankau, J. Schauer, J. Winkler, H. Wirtz (Leipzig, Germany)
| |
Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients A. Peacock, G. Burgess, T. Parpia, R. Barst (Glasgow, Sandwich, United Kingdom; New York, United States Of America)
| |
Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH) P. Corris, G. Burgess, T. Parpia, R. Barst (Newcastle upon Tyne, Sandwich, United Kingdom; New York, United States Of America)
| |
Effects of sildenafil on 6-minute walk distance (6MWD) and WHO functional class (FC) in pulmonary arterial hypertension (PAH) patients after 1 year of treatment O. Sitbon, G. Burgess, T. Parpia, H. Ghofrani (Clamart, France; Sandwich, United Kingdom; Giessen, Germany)
| |
Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy R. L. Benza, R. Barst (Birmingham, New York, United States Of America)
| |
STRIDE-2 trial: a placebo-controlled study for sitaxsentan in PAH N. Galie, D. Langleben, R. Barst (Bologna, Italy; Montreal, Canada; New York, United States Of America)
| |
Haemodynamics during vasodilator test comparing urapidil and nicardipine to NO in pulmonary arterial hypertension B. Gressens, D. Castanares, J. Jamart, P. Bulpa, E. Installé, P. Evrard (Yvoir, Belgium)
| |